The 9MMHER2-Positive Gastric Cancer Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Pipeline drugs expected to provide an opportunity of more than USD 1,218.3 million during the forecast year.
150+ ongoing clinical trials….
Disease Overview
HER2-positive gastric cancer refers to a specific subtype of gastric (stomach) cancer where cancer cells have an overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This overexpression is typically detected through diagnostic tests like immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). HER2-positive gastric cancer tends to be more aggressive and may have a poorer prognosis compared to HER2-negative gastric cancer. However, targeted therapies, such as trastuzumab (Herceptin) in combination with chemotherapy, have shown effectiveness in treating HER2-positive gastric cancer, improving outcomes for patients with this subtype of the disease.
Report has deeply investigated patient’s presentation and tailored treatment
Patients with HER2-Positive Gastric Cancer – Tailoring Treatment Read more…..
Report has Covered Granular-level Analysis in Each Mapped Market
HER2-Positive Gastric Cancer Disease Burden Analysis: (Result shown here is reflecting from meta-analysis, and CSP Analytics Solutions Analysis)
Experts indicated prevalence increased significantly across regions, but gaps in estimates still persist.
Our research report has provided crystal clear view of prevalent pool across regions. Since epidemiology estimation accompanied with lot of complexity, our report has streamlined the estimation process for enhancing market understanding.
Report has also highlighted, impact of improvements in diagnosis, on diagnosis rate (%).
HER2-Positive Gastric Cancer Cases: 9MM
HER2-Positive Gastric Cancer accountsfor XX million cases in 9MM
HER2-Positive Gastric Cancer accountsfor XX million cases in United States
HER2-Positive Gastric Cancer accountsfor XX million cases in China
HER2-Positive Gastric Cancer accountsfor XX million cases in India
HER2-Positive Gastric Cancer accountsfor XX million cases in Japan
HER2-Positive Gastric Cancer accountsfor XX million cases in Rest of World
Treatment Landscape:
This report section deals with the treatment strategies adopted by healthcare professional while dealing across patients’ segments. Also provided gaps in current treatment and upcoming treatment options.
The treatment of HER2-Positive Gastric Cancer typically involves a multidisciplinary approach, which may include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The specific treatment plan depends on factors such as the stage and location of the cancer, the patient's overall health and preferences, and any underlying genetic mutations.
Report section covers detailed around various types of available treatments
Chemotherapy
Targeted Therapies
Immunotherapy
Also covers patient segment targeted by each therapy type: This section address concerns regarding unaddressed patient pool
Several companies and institutions collaborating to bring out the appropriate treatment solutions
Our report analysis revealed that, there are tremendous opportunities exits in the market in order to close the current market gaps
Recent clinical guidelines enable the streamlining the treatment approaches
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Patient Segment Coverage:
Drug
Targeted Patient Segment
Chemotherapy
XX
Targeted Therapies
XX
Immunotherapy
XX
Upcoming Therapy Assessment (Pipeline Analysis)
Report also provided promising therapy assessment including existing therapies, and upcoming therapy
Novel drug target assessment
Comparable efficacy and safety profiles of key drugs prescribed in each mapped geography
Expected launch of key pipeline assets
Report alsoinvestigated novel therapy development
Experts Opinion on the matter of accepting novel treatment options
Promising molecules advantages offer over existing therapy
Impact assessment of pipeline assets
Drug analogue analysis
Expected annual cost of therapy
Market space expected to be captured by emerging therapeutic options
Market Segmentation Analysis by:
By Stages
Early-stage (I and II)
Locally advanced (III)
Metastatic (IV)
By Treatment Line
First-Line Treatment
Second-Line Treatment
By Type of Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Market Enablers: Explored in the report
Importance of HER2 Status in Treatment Selection: HER2 overexpression or amplification has been identified as a significant driver of tumor growth and progression in gastric cancer. As a result, HER2 testing has become standard practice in gastric cancer diagnosis and treatment planning. The availability of HER2-targeted therapies has thus become crucial, driving market growth.
Growing Incidence of Gastric Cancer
Clinical Efficacy of HER2-Targeted Therapies
Regulatory Approvals and Reimbursement Policies
Untreated Prevalent Pool of HER2-Positive Gastric Cancer
Focus on Early Detection and Screening
Continued investments in research and developmental activities by pharmaceutical companies, and academic institutions contribute to the development of innovative diagnostic tools, treatments, and other therapies.
Market Challenges: Explored in the report
Access Disparities: Disparities in access to healthcare services and treatments exist globally, with patients in certain regions or socio-economic groups facing barriers to accessing HER2-targeted therapies. Addressing these disparities requires efforts to improve healthcare infrastructure, increase awareness, and provide financial assistance programs.
Heterogeneity of Disease
High Cost of Treatment
Limited Treatment Options
Resistance to Treatment
Clinical Trial Design and Patient Recruitment
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Market Unmet Need Analysis
5-Europe HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World, HER2-Positive Gastric Cancer Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
Genentech
Merck
Iksuda Therapeutics Ltd.
Celularity Incorporated
Acepodia Biotech, Inc.
Seagen Inc.
Jiangsu HengRui Medicine Co., Ltd.
Novartis Pharmaceuticals
Mersana Therapeutics
Bellicum Pharmaceuticals
BioInvent International AB
Bolt Biotherapeutics, Inc.
Merrimack Pharmaceuticals
Hanmi Pharmaceutical Company Limited
DualityBio Inc.
Cellid Co., Ltd.
Jazz Pharmaceuticals
Bristol Myers Squibb (BMS)
Others
Reason to buy this report:
Fostering Understanding on HER2-Positive Gastric Cancer Disease Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)
